Tobramycin

Paul G. Auwaerter, M.D., Paul A. Pham, Pharm.D.

INDICATIONS

UTI
Septicemia, including serious central nervous system infections (use in combination)
Lower respiratory tract infections (use in combination)
Complicated urinary tract infections
Intra-abdominal infections, including peritonitis (use in combination)
Skin, bone, and skin structure infections (use in combination)
Management of cystic fibrosis with P. aeruginosa (as tobramycin inhalation)
- Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in less than one second (FEV1) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.
Treatment of ocular infections (uncomplicated conjunctivitis-ophthalmic solution)

Pneumonia, hospital-acquired (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, or a third-/fourth-generation cephalosporin)
- Considered in patients with MDR gram negative infections.
- Efficacy is unproven.
Pseudomonal infections (in combination with a beta-lactam, beta-lactam/beta-lactamase inhibitor, carbapenem or a third/fourth-generation cephalosporin)
Bronchiectasis, non-cystic fibrosis (inhaled)
Otitis external (tobramycin/dexamethasone topical)

There's more to see -- the rest of this topic is available only to subscribers.